Cargando…

Vorinostat in the acute neuroinflammatory form of X‐linked adrenoleukodystrophy

OBJECTIVE: To identify a pharmacological compound targeting macrophages, the most affected immune cells in inflammatory X‐linked adrenoleukodystrophy (cerebral X‐ALD) caused by ABCD1 mutations and involved in the success of hematopoietic stem cell transplantation and gene therapy. METHODS: A compara...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zierfuss, Bettina, Weinhofer, Isabelle, Kühl, Jörn‐Sven, Köhler, Wolfgang, Bley, Annette, Zauner, Katharina, Binder, Johannes, Martinović, Ksenija, Seiser, Christian, Hertzberg, Christoph, Kemp, Stephan, Egger, Gerda, Leitner, Gerda, Bauer, Jan, Wiesinger, Christoph, Kunze, Markus, Forss‐Petter, Sonja, Berger, Johannes
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7261758/ https://www.ncbi.nlm.nih.gov/pubmed/32359032 http://dx.doi.org/10.1002/acn3.51015

Ejemplares similares

Abcd1 deficiency accelerates cuprizone-induced oligodendrocyte loss and axonopathy in a demyelinating mouse model of X-linked adrenoleukodystrophy
por: Martinović, Ksenija, et al.
Publicado: (2023)

Impaired plasticity of macrophages in X-linked adrenoleukodystrophy
por: Weinhofer, Isabelle, et al.
Publicado: (2018)

Targeting foam cell formation in inflammatory brain diseases by the histone modifier MS‐275
por: Zierfuss, Bettina, et al.
Publicado: (2020)

Neurofilament light chain as a potential biomarker for monitoring neurodegeneration in X-linked adrenoleukodystrophy
por: Weinhofer, Isabelle, et al.
Publicado: (2021)

Biomarker-based risk prediction for the onset of neuroinflammation in X-linked adrenoleukodystrophy
por: Weinhofer, Isabelle, et al.
Publicado: (2023)

Evaluation of Retinoids for Induction of the Redundant Gene ABCD2 as an Alternative Treatment Option in X-Linked Adrenoleukodystrophy
por: Weber, Franziska D., et al.
Publicado: (2014)

X-linked adrenoleukodystrophy: very long-chain fatty acid metabolism is severely impaired in monocytes but not in lymphocytes
por: Weber, Franziska D., et al.
Publicado: (2014)

Pathophysiology of X-linked adrenoleukodystrophy()
por: Berger, J., et al.
Publicado: (2014)

The genetic landscape of X-linked adrenoleukodystrophy: inheritance, mutations, modifier genes, and diagnosis
por: Wiesinger, Christoph, et al.
Publicado: (2015)

Histone deacetylase inhibitors valproic acid and vorinostat enhance trastuzumab-mediated antibody-dependent cell-mediated phagocytosis
por: Laengle, Johannes, et al.
Publicado: (2020)

CD1 Gene Polymorphisms and Phenotypic Variability in X-Linked Adrenoleukodystrophy
por: Barbier, Mathieu, et al.
Publicado: (2012)

Abcd2 Is a Strong Modifier of the Metabolic Impairments in Peritoneal Macrophages of Abcd1-Deficient Mice
por: Muneer, Zahid, et al.
Publicado: (2014)

Saturated very long-chain fatty acids regulate macrophage plasticity and invasiveness
por: Zierfuss, Bettina, et al.
Publicado: (2022)

ABCD1 Transporter Deficiency Results in Altered Cholesterol Homeostasis
por: Buda, Agnieszka, et al.
Publicado: (2023)

Peroxisomal very long-chain fatty acid transport is targeted by herpesviruses and the antiviral host response
por: Weinhofer, Isabelle, et al.
Publicado: (2022)

Peroxisomes in brain development and function☆
por: Berger, Johannes, et al.
Publicado: (2015)

Evolution of adrenoleukodystrophy model systems
por: Montoro, Roberto, et al.
Publicado: (2021)

Vorinostat—An Overview
por: Bubna, Aditya Kumar
Publicado: (2015)

Bezafibrate for X-Linked Adrenoleukodystrophy
por: Engelen, Marc, et al.
Publicado: (2012)

Phospholipase D1 is upregulated by vorinostat and confers resistance to vorinostat in glioblastoma
por: Kang, Dong Woo, et al.
Publicado: (2020)

Alterations in the Plasma Levels of Specific Choline Phospholipids in Alzheimer’s Disease Mimic Accelerated Aging
por: Dorninger, Fabian, et al.
Publicado: (2018)

Molecular Biomarkers for Adrenoleukodystrophy: An Unmet Need
por: Honey, Madison I. J., et al.
Publicado: (2021)

Epigenetic biomarkers in cancer
por: Egger, Gerda
Publicado: (2018)

Vorinostat in solid and hematologic malignancies
por: Siegel, David, et al.
Publicado: (2009)

Epigenetic Regulation of a Murine Retrotransposon by a Dual Histone Modification Mark
por: Brunmeir, Reinhard, et al.
Publicado: (2010)

Correction: Epigenetic Regulation of a Murine Retrotransposon by a Dual Histone Modification Mark
por: Brunmeir, Reinhard, et al.
Publicado: (2011)

Childhood cerebral adrenoleukodystrophy
por: Mittal, Aliza, et al.
Publicado: (2014)

Antioxidants Impair Anti-Tumoral Effects of Vorinostat, but Not Anti-Neoplastic Effects of Vorinostat and Caspase-8 Downregulation
por: Bergadà, Laura, et al.
Publicado: (2014)

Attitudes of Patients with Adrenoleukodystrophy towards Sex-Specific Newborn Screening
por: Yska, Hemmo A. F., et al.
Publicado: (2023)

Postural Body Sway as Surrogate Outcome for Myelopathy in Adrenoleukodystrophy
por: van Ballegoij, Wouter J. C., et al.
Publicado: (2020)

Disease progression in women with X-linked adrenoleukodystrophy is slow
por: Huffnagel, Irene C., et al.
Publicado: (2019)

Vorinostat (SAHA) and Breast Cancer: An Overview
por: Wawruszak, Anna, et al.
Publicado: (2021)

Epigenomics of cancer – emerging new concepts
por: Hassler, Melanie R., et al.
Publicado: (2012)

Spinal cord atrophy as a measure of severity of myelopathy in adrenoleukodystrophy
por: van de Stadt, Stephanie I. W., et al.
Publicado: (2020)

Multiple sclerosis in an adrenoleukodystrophy carrier
por: Jenkins, Thomas, et al.
Publicado: (2011)

Anesthesia in a child with adrenoleukodystrophy
por: Yang, Hun-Ju, et al.
Publicado: (2014)

Disturbed neurotransmitter homeostasis in ether lipid deficiency
por: Dorninger, Fabian, et al.
Publicado: (2019)

Clinical Efficacy of Vorinostat in a Patient with Leiomyosarcoma
por: Lee, Jin, et al.
Publicado: (2012)

The Effect of Vorinostat on the Development of Resistance to Doxorubicin in Neuroblastoma
por: Lautz, Timothy B., et al.
Publicado: (2012)

Immune effectors required for the therapeutic activity of vorinostat
por: Kepp, Oliver, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_orf277qhovti6vfntlqr3ukesr